Omnicell, Inc. (NASDAQ:OMCL) Stock Has Average Price Target of $57.86 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Omnicell, with seven buy ratings and two holds. The average 12-month price target is $57.86, above the reported share price of $35.82.
• Omnicell’s latest quarterly results exceeded expectations, with adjusted earnings of $0.94 per share versus the $0.47 consensus estimate and revenue of $312.21 million, up 7.4% year over year.
• Institutional ownership stands at 97.70%, with BlackRock acquiring an approximately $313 million position and several other investment firms adding new or expanded stakes.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $57.86.

A number of brokerages have weighed in on OMCL. Zacks Research upgraded Omnicell from a "strong sell" rating to a "hold" rating in a research note on Monday, September 7th. Wells Fargo & Company cut their target price on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. KeyCorp reiterated an "overweight" rating on shares of Omnicell in a research note on Monday, August 24th. Piper Sandler reissued an "overweight" rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 18th.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.82 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The firm has a 50-day moving average of $34.66 and a two-hundred day moving average of $38.42. The stock has a market cap of $1.63 billion, a P/E ratio of 42.64, a PEG ratio of 0.87 and a beta of 0.98. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same period last year, the firm earned $0.45 earnings per share. The company's revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, research analysts expect that Omnicell will post 1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $313,044,000. First Light Asset Management LLC bought a new stake in shares of Omnicell in the 1st quarter valued at approximately $16,351,000. WCM Investment Management LLC acquired a new stake in shares of Omnicell during the 1st quarter valued at approximately $9,783,000. Empowered Funds LLC raised its position in shares of Omnicell by 4,229.9% during the 1st quarter. Empowered Funds LLC now owns 262,043 shares of the company's stock valued at $8,747,000 after acquiring an additional 255,991 shares in the last quarter. Finally, Burney Co. bought a new position in Omnicell during the first quarter worth $7,118,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company's offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.